Aggressive B-Cell Lymphomas by Naresh, Kikkeri N. et al.
Hindawi Publishing Corporation
Advances in Hematology
Volume 2012, Article ID 604603, 1 page
doi:10.1155/2012/604603
Editorial
Aggressive B-CellLymphomas
Kikkeri N. Naresh,1 IanMagrath,2 Martine Raphael,3 and Lorenzo Leoncini4
1Department of Pathology, Imperial College Healthcare NHS Trust, London W12 OHS, UK
2International Network for Cancer Treatment and Research, B1180 Brussels, Belgium
3Service d’H´ ematologie et Immunologie Biologiques, Cytog´ en´ etique, Traitement de l’H´ emophilie et Th´ erapie Transfusionnelle,
94275 Le Kremlin-Bicˆ etre Cedex, France
4Department of Pathology, University of Siena, 53100 Siena, Italy
Correspondence should be addressed to Lorenzo Leoncini, leoncinil@unisi.it
Received 23 February 2012; Accepted 23 February 2012
Copyright © 2012 Kikkeri N. Naresh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Aggressive B-cell lymphomas (ABLs) are a group of B-cell
malignancies, that is, a relatively common form of cancer
across the world. This issue on aggressive B-cell lymphomas
compiles 12 exciting manuscripts, most of which are very
meticulously performed reviews of the available current
literature.
Three areas of lymphoma pathology and biology that
are leading to a greater understanding of relatively recently
deﬁned entities are discussed. These include anaplastic
lymphoma kinase (ALK)-positive large B-cell lymphoma
(ALK+ LBCL), and the so-called grey zone lymphomas
or lymphomas with intermediate features and the post-
transplant lymphoproliferative disorders. ALK+ LBCL are
characterised by gene rearrangement involving clathrin
and ALK genes (t(2;17)(p23;q23)). Grey zone lymphomas
include two unclassiﬁable B-cell lymphomas, one with
features intermediate between diﬀuse large B-cell lymphoma
(DLBCL) and classical Hodgkin lymphoma (cHL) and the
second with features intermediate between DLBCL and
Burkitt lymphoma (BL).
The biology of common lymphomas is addressed in two
manuscripts. M. Rossi et al. review the current literature
on molecular subsets of DLBCL, the distinction between
DLBCL and BL, and gene expression characteristics of the
grey zone lymphomas. This paper is accompanied by M.
Cacciatore et al.’s manuscript that explores the importance
of the microenvironment in lymphoma biology.
Two of the manuscripts deal with those aspects of
endemic BL pathogenesis that have hitherto not been
explored in great depth. The paper by S. Mannucci et al.
explore the possibility of Euphorbia tirucalli acting as a
cofactor in BL. They show that, in lymphoblastoid cell lines,
E. tirucalli can modulate the EBV latency genes, result in
polysomy for chromosome 8, and cause upregulation of c-
MYC. Furthermore, Dr. C. van den Bosch raises question
about a possible role for RNA viruses in the pathogenesis of
BL.
Dr. I. Magrath reviews the evolution of BL treatment
in Africa—from cyclophosphamide monotherapy to mul-
tiagent combination chemotherapy including central ner-
vous system prophylaxis using combinations of cyclophos-
phamide, vincristine, prednisone, and methotrexate. He also
highlights the beneﬁts of collaboration between resource-
rich and resource-poor settings. P. Vishnu and D. M.
Aboulaﬁa review how the treatment of HIV-associated
lymphomas has evolved since the introduction of highly
activeantiretroviraltherapy(HAART).Theuseofrituximab,
in conjunction with multiagent chemotherapy, and where
required high-dose chemotherapy (HDCT) and autologous
stem cell rescue (ASCT) have all contributed to the success
of treating HIV lymphomas. Treatment of ABL is further
reviewed in two paper—one on ASCT in DLBCL and the
other on novel therapies by K. Foon et al. To complete
the issue, S. Donnou reviews the currently available murine
modelsusefulforstudyinglymphomagenesis,thelymphoma
microenvironment, and the eﬃcacy of new therapies.
By compiling these paper, we hope to enrich our readers
and researchers with respect to these particularly common,
yet usually highly treatable aggressive B-cell malignancies.
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